Skip to main content
Clinical Trials/NCT05830110
NCT05830110
Active, Not Recruiting
N/A

Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease

Synergic Medical Technologies, Inc.2 sites in 1 country30 target enrollmentMarch 1, 2023

Overview

Phase
N/A
Intervention
Sham vibrotactile coordinated reset
Conditions
Parkinson's Disease
Sponsor
Synergic Medical Technologies, Inc.
Enrollment
30
Locations
2
Primary Endpoint
Movement Disorder Society - Change in Universal Parkinson Disease Rating Scale (MDS-UPDRS)
Status
Active, Not Recruiting
Last Updated
7 days ago

Overview

Brief Summary

The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses a novel stimulation pattern to disrupt the pathophysiological mechanism that is responsible for PD symptoms and thus restore motor function.

Detailed Description

Up to thirty adults with bilateral, moderate stage idiopathic PD will be enrolled in this longitudinal study. Participants will serve as their own control, receiving alternating active and sham therapy at two-month intervals. This longitudinal protocol will be open-ended to enable continued treatment to those interested / motivated. Study treatment will consist of daily, four-hour vibrotactile Coordinated Reset (vCR) stimulation sessions on a continual basis. All daily vCR stimulation sessions will occur at the participant's home (ON-medication) and can be broken up into two, two-hour blocks (with no more than 12 hours between stimulation blocks) to be less cumbersome and better integrate into the participant's daily life. Daily home-based treatment will be unsupervised, though timely support is guaranteed by Synergic Medical Technologies (SMT) support staff when needed (e.g., when usability or IT issues arise). Daily stimulation / device usage will be automatically logged by the device and continuously monitored by SMT staff, meanwhile participants will keep a med diary so we can monitor their med usage (and how it relates to extended exposure) over time. Participants will be able to transition to an as-needed basis with treatment after four months and once they are familiar with the treatment and their body's response to it, to better alleviate PD symptoms.

Registry
clinicaltrials.gov
Start Date
March 1, 2023
End Date
June 1, 2026
Last Updated
7 days ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • between the ages 45 and 90
  • diagnosis of bilateral, moderate stage idiopathic PD
  • qualify for EEG procedures

Exclusion Criteria

  • on dopamine agonist medications and exhibiting compulsive behaviors

Arms & Interventions

Sham vibrotactile coordinated reset

mechanical vibrotactile stimulation to the fingers in a defined pattern

Intervention: Sham vibrotactile coordinated reset

Active vibrotactile coordinated reset

mechanical vibrotactile stimulation to the fingers in a defined pattern

Intervention: Active Vibrotactile Coordinated Reset

Outcomes

Primary Outcomes

Movement Disorder Society - Change in Universal Parkinson Disease Rating Scale (MDS-UPDRS)

Time Frame: baseline, 2 months, 4 months

Change in MDS-UPDRS score using Part 3 of the scale.

Study Sites (2)

Loading locations...

Similar Trials